County Medical Community-based, Cardiovascular Risk Stratified Integrated Care Model: a Pragmatic Cluster Randomised Control Trial
Launched by PEKING UNIVERSITY · Mar 4, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the RISIMA model, is looking at how a special healthcare program can help people with conditions like high blood pressure (hypertension) and type 2 diabetes, as well as those at risk for heart disease. The study is taking place in a county where family health teams will work together to provide better care and management for these patients. The goal is to see if this new approach can improve health outcomes for people in the community.
To be eligible for this trial, participants need to be between 40 and 70 years old, live in the county where the study is happening, and already be registered with a family doctor team in their area. They should have either hypertension or diabetes. Participants will receive support and care tailored to their needs, and the trial is currently active but not looking for new volunteers. It’s important to note that some individuals may not be able to participate if they have other serious health issues, live too far from the health center, or are pregnant or breastfeeding. Overall, this trial aims to make a real difference in managing these common health conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged between 40 and 70 years old;
- • 2. Patients with hypertension or diabetes;
- • 3. Permanent residents of the county where the research is conducted;
- • 4. Already signed up with the family doctor team in the township where the research is located.
- Exclusion Criteria:
- • 1. Unable to independently carry out the interventions required for the study;
- • 2. Residing far from the village or township health center where the research is located, making it difficult to cooperate with visits;
- • 3. Patients who refuse to participate;
- • 4. Patients with comorbidities such as cancer that may interfere with the study visits or intervention effects;
- • 5. Pregnant or lactating women
About Peking University
Peking University is a prestigious institution located in Beijing, China, recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, Peking University leverages its extensive academic resources and collaborative networks to drive innovative healthcare solutions. The university's focus on rigorous scientific methodologies and adherence to ethical standards ensures the integrity and reliability of its clinical research initiatives. By fostering interdisciplinary partnerships, Peking University aims to translate groundbreaking discoveries into tangible health benefits, contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sanming, Fujian, China
Liuzhou, Guangxi, China
Liuzhou, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported